ClinicalTrials.gg
RecruitingNCT07137598Updated Oct 16, 2026

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

A Phase 2 interventional study of Afimkibart and Placebo in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Recruiting at 65 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 16, 20264 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Planned enrollment
64th of 141
160 · median 132
Started
2025
the only one that year
Phase 2
20 of 219
2 open now
Registered
218th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 64th largest by planned enrollment of the 141 interventional ones that give a count, is the only one that started in 2025, is one of 20 in phase 2, and was the 218th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has moderate to severe active RA defined by the presence of >=6 swollen joints and >=6 tender joints at screening and baseline (based on 66/68-joint count)
  • Diagnosis of RA for >=3 months and also fulfills the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria for RA
  • Demonstrated an inadequate response or loss of response to or intolerance to >=1 conventional synthetic disease-modifying antirheumatic drug (csDMARD)

Exclusion criteria

Exclusion Criteria:

  • Have failed more than two TNF inhibitors or JAK inhibitors
  • Class IV RA according to ACR revised response criteria (Hochberg et al. 1992)
  • Past or current use of other biologic disease-modifying antirheumatic drugs (bDMARDs) (excluding TNF inhibitors) or rituximab
  • Treatment with therapy within 4 weeks or within 5 half-lives of the investigational therapy, whichever is longer, prior to initiation of study treatment.
  • History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA
  • Has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, or intra-tendon sheath in the preceding 8 weeks prior to the first dose of study drug
  • History of a severe allergic reaction or anaphylactic reaction or known to any component of the study drug (or its ) and/or other products in the same class
  • Any major surgery within 6 weeks prior to screening or a major surgery planned during the study
  • Any serious, chronic and/or unstable pre-existing medical, psychiatric, or other- condition
  • History of , with the exception non- basal cell or cutaneous squamous cell cancer adequately treated with electrodesiccation and curettage or resection or in situ cervical cancer adequately treated and cured
  • Participants with severe chronic or recurrent viral, bacterial, parasitic, or fungal infections
  • History of active virus (HBV), virus (HCV), or (HIV) infection
  • History of organ transplant
  • Any identified confirmed congenital or acquired immunodeficiency
  • Abnormal laboratory values and liver function test
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Afimkibart Group I

    Participants will receive afimkibart via subcutaneous (SC) injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Group II

    Participants will receive afimkibart via SC injection.

    Drug: Afimkibart

  • Placebo comparator
    Placebo

    Participants will receive afimkibart matched placebo via SC injection.

    Drug: Placebo

Interventions

  • Afimkibart will be administered as SC injection.

    Also known as: PF 06480605, RVT-3101, RO7790121

  • DrugPlacebo

    Placebo will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP)

    Time frame: Baseline, At Week 14

Secondary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%), 50% or 70% Improvement (ACR20/ACR50/ACR70)

    Time frame: At Week 14

  2. Change from Baseline Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS28-ESR) Score

    Time frame: Baseline, At Week 14 and Week 24

  3. Change From Baseline in the ACR Core Set - Swollen Joint Count (SJC)

    Time frame: Baseline, At Week 14 and Week 24

  4. Change From Baseline in the ACR Core Set - Tender Joint Count (TJC)

    Time frame: Baseline, At Week 14 and Week 24

  5. Change From Baseline in the ACR Core Set - Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)

    Time frame: Baseline, At Week 14 and Week 24

  6. Change From Baseline in the ACR Core Set - Patient's Global Assessment of Arthritis Pain-Visual Analog Scale (PGA Arthritis Pain-VAS)

    Time frame: Baseline, At Week 14 and Week 24

  7. Change From Baseline in the ACR Core Set - Patient's Global Assessment of Disease Activity-Visual Analog Scale (PaGADA-VAS)

    Time frame: Baseline, At Week 14 and Week 24

  8. Change From Baseline in the ACR Core Set - Health Assessment Questionnaire- Disability Index (HAQ-DI)

    Time frame: Baseline, At Week 14 and Week 24

  9. Change From Baseline in the ACR Core Set - High-sensitivity C-reactive Protein (hsCRP)

    Time frame: Baseline, At Week 14 and Week 24

  10. Change from Baseline in ACR20, ACR50 and ACR70 Response Rate

    Time frame: Baseline, At Week 24

  11. Change from Baseline in Simplified Disease Activity Index (SDAI) Score

    Time frame: Baseline, At Week 14 and Week 24

  12. Change from Baseline in Clinical Disease Activity Index (CDAI) Score

    Time frame: Baseline, At Week 14 and Week 24

  13. Change from Baseline in Short Form-36 Health Survey (SF-36) Score

    Time frame: Baseline, At Week 14 and Week 24

  14. Change from Baseline Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP) Score

    Time frame: Baseline, At Week 24

  15. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to Week 38

  16. Serum Concentration of RO7790121 at Specified Timepoints

    Time frame: Up to Week 38

  17. Percentage of Participants With Anti-Drug Antibodies

    Time frame: Baseline, Up to Week 38

07

Study locations

65 of 65 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 16 months is close to that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 22, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Apr 17, 2027
CompletionEst.
Oct 2, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 3 sites removed
Show 4 added (3 United States, 1 Denmark)
  • Arizona Arthritis & Rheumatology Associates, P.C. · Avondale, United States
  • Equity Medical · Owensboro, United States
  • DM Clinical Research at Tomball · Tomball, United States
  • Sjllands Universitetshospital · Køge, Denmark
Show 3 removed
  • Equity Medical · The Bronx, United States
  • DM Clinical Research · Tomball, United States
  • Sjllands Universitetshospital · Kge, Denmark
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    4 sites added, 3 sites removed
    Show 4 added (3 United States, 1 Denmark)
    • Arizona Arthritis & Rheumatology Associates, P.C. · Avondale, United States
    • Equity Medical · Owensboro, United States
    • DM Clinical Research at Tomball · Tomball, United States
    • Sjllands Universitetshospital · Køge, Denmark
    Show 3 removed
    • Equity Medical · The Bronx, United States
    • DM Clinical Research · Tomball, United States
    • Sjllands Universitetshospital · Kge, Denmark
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07137598
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Dec 5, 2025
Primary completion
Apr 17, 2027 (estimated)
Completion
Oct 2, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Reference Study ID Number: WA45846 https://forpatients.roche.com/ No attachments to email below.
Contact
global.rochegenentechtrials@roche.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion